These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25386164)

  • 21. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H; Moschen A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease.
    Dixon JB
    Clin Liver Dis; 2014 Feb; 18(1):129-46. PubMed ID: 24274869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic histology in obese patients undergoing bariatric surgery.
    Machado M; Marques-Vidal P; Cortez-Pinto H
    J Hepatol; 2006 Oct; 45(4):600-6. PubMed ID: 16899321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Non-alcoholic fatty liver].
    Tagle Arrospide M
    Rev Gastroenterol Peru; 2003; 23(1):49-57. PubMed ID: 12768215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of weight loss on nonalcoholic fatty liver disease.
    Rafiq N; Younossi ZM
    Semin Liver Dis; 2008 Nov; 28(4):427-33. PubMed ID: 18956298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASH and NASH.
    Scaglioni F; Ciccia S; Marino M; Bedogni G; Bellentani S
    Dig Dis; 2011; 29(2):202-10. PubMed ID: 21734385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis.
    Ganguli S; DeLeeuw P; Satapathy SK
    Hepat Med; 2019; 11():159-178. PubMed ID: 31814783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation and non-alcoholic fatty liver disease.
    Zezos P; Renner EL
    World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical aspects of non-alcoholic fatty liver disease.
    Björnsson E
    Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.
    Hannah WN; Harrison SA
    Clin Liver Dis; 2016 May; 20(2):339-50. PubMed ID: 27063273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.